EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of Aryl Pyrazolopyrimidines as Toll‐Like Receptor 7 Agonists

Ji Hwan Kim, Youngshim Lee, Seunghyun Ahn, Dongsoo Koh, Yoongho Lim, Young Han Lee, Dong-Ho Bae, Soon Young Shin

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Ji Hwan Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bioscience and Biotechnology, BMIC, Konkuk University, Seoul, Korea. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Pyrimidines, Pyrazoles, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Compounds containing pyrazolopyrimidine scaffolds were designed and synthesized as toll‐like receptor 7 (TLR7) agonists. Thirty‐three compounds, including 22 novel compounds, were prepared, and their structures were identified using nuclear magnetic resonance spectroscopy and mass spectrometry. TLR7 agonist activity was determined in HEK‐Blue hTLR7 reporter cells. Among the compounds tested, 2‐((4‐methoxyphenyl)amino)‐7‐(pyridin‐2‐yl)pyrazolo[1,5 ‐a ]pyrimidine‐3‐carbonitrile showed the highest activity, and further in vitro biological experiments were performed using this compound. Treatment with the title compound activated the TLR7‐mediated NF‐κB pathway, triggering the IRAK4‐IKKα/β‐IκBα‐p65 NF‐κB signaling cascade, which led to an increase in the expression of NF‐κB‐regulated innate cytokines such as TNFα and IL‐1β in RAW264.7 macrophages. These findings suggest that the title compound acts as a TLR7 agonist and enhances the innate immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7PyrimidinesPyrazolesDrug DesignNF-kappa BHumansMiceAnimalsRAW 264.7 CellsHEK293 CellsSignal TransductionTumor Necrosis Factor-alphaInterleukin-1 Receptor-Associated KinasesInterleukin-1betaImmunity, InnateMacrophagesStructure-Activity Relationship

Stichwörter der Autor:innen

NF‐κBRAW264.7 macrophageinnate immunityinterleukin 1βpyrazolo[1,5‐a]pyrimidinetoll‐like receptor 7

Substanzen

Toll-Like Receptor 7PyrimidinesPyrazolesNF-kappa BTumor Necrosis Factor-alphaInterleukin-1 Receptor-Associated KinasesInterleukin-1betaTLR7 protein, human

Autor:innen und Institutionen

  • Division of Bioscience and Biotechnology, BMIC, Konkuk University, Seoul, Korea.
  • Department of Applied Chemistry, Dongduk Women's University, Seoul, Korea.
  • Department of Biological Sciences, Konkuk University, Seoul, Korea.
  • Department of Food Sciences and Biotechnology of Animal Resources, Konkuk University, Seoul, Korea.
  • Cancer and Metabolism Institute, Konkuk University, Seoul, Korea.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Kim, J. H., Lee, Y., Ahn, S., Koh, D., Lim, Y., Lee, Y. H., Bae, D. H., & Shin, S. Y. (2025). Design, Synthesis, and Biological Evaluation of Aryl Pyrazolopyrimidines as Toll‐Like Receptor 7 Agonists. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70056

Vancouver

Kim JH, Lee Y, Ahn S, Koh D, Lim Y, Lee YH, et al. Design, Synthesis, and Biological Evaluation of Aryl Pyrazolopyrimidines as Toll‐Like Receptor 7 Agonists. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70056

BibTeX
@article{Kim2025,
  author = {Kim, Ji Hwan and Lee, Youngshim and Ahn, Seunghyun and Koh, Dongsoo and Lim, Yoongho and Lee, Young Han and Bae, Dong-Ho and Shin, Soon Young},
  title = {Design, Synthesis, and Biological Evaluation of Aryl Pyrazolopyrimidines as Toll‐Like Receptor 7 Agonists},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70056}
}
Kostenlos starten →